Literature DB >> 11034110

Low urinary 6-sulphatoxymelatonin levels in patients with coronary artery disease.

L Girotti1, M Lago, O Ianovsky, J Carbajales, M V Elizari, L I Brusco, D P Cardinali.   

Abstract

A decrease in nocturnal serum melatonin levels was reported in patients with clinically uncharacterized coronary artery disease. To assess whether there was a correlation between melatonin production and disease stage, we measured the nocturnal urinary excretion of 6-sulphatoxymelatonin (an index of blood melatonin concentration) in patients with chronic stable or unstable coronary disease and in a group of age-matched controls. Three groups of individuals were studied: a) 24 healthy subjects (mean age: 63 +/- 13 yr); b) 32 patients with chronic, stable, coronary disease (62 +/- 11 yr); and c) 27 patients with unstable angina (62 +/- 12 yr). For 6-sulphatoxymelatonin measurement, urine was collected from 18:00 to 06:00 hr, within 48 hr of hospitalization in the case of unstable angina. 6-Sulphatoxymelatonin was measured by a specific radioimmunoassay. Urinary 6-sulphatoxymelatonin excretion was significantly lower in unstable angina patients than in healthy subjects or in patients with stable angina. 6-Sulphatoxymelatonin correlated negatively with age in healthy subjects, but not in coronary patients. 6-Sulphatoxymelatonin excretion in patients treated with beta-adrenoceptor blockers did not differ significantly from coronary patients not receiving beta-blockers. The results indicate that patients with coronary disease have a low melatonin production rate, with greater decreases in those with higher risk of cardiac infarction and/or death.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11034110     DOI: 10.1034/j.1600-079x.2000.290302.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  18 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

2.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

Review 3.  Role of melatonin in neurodegenerative diseases.

Authors:  V Srinivasan; S R Pandi-Perumal; G Jm Maestroni; A I Esquifino; R Hardeland; D P Cardinali
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

Review 4.  Melatonin, mitochondria, and the metabolic syndrome.

Authors:  Daniel P Cardinali; Daniel E Vigo
Journal:  Cell Mol Life Sci       Date:  2017-08-17       Impact factor: 9.261

5.  Effect of melatonin on changes in locomotor activity rhythm of Syrian hamsters injected with beta amyloid peptide 25-35 in the suprachiasmatic nuclei.

Authors:  Analía M Furio; Rodolfo A Cutrera; Víctor Castillo Thea; Santiago Pérez Lloret; Patricia Riccio; Roberto L Caccuri; Luis L Brusco; Daniel P Cardinali
Journal:  Cell Mol Neurobiol       Date:  2002-12       Impact factor: 5.046

6.  Low urinary 6-sulfatoxymelatonin levels in patients with severe congestive heart failure.

Authors:  Luis Girotti; Manuel Lago; Oscar Ianovsky; Marcelo V Elizari; Andrés Dini; Santiago Pérez Lloret; Liliana E Albornoz; Daniel P Cardinali
Journal:  Endocrine       Date:  2003-12       Impact factor: 3.633

7.  Chronobiology of Melatonin beyond the Feedback to the Suprachiasmatic Nucleus-Consequences to Melatonin Dysfunction.

Authors:  Rüdiger Hardeland
Journal:  Int J Mol Sci       Date:  2013-03-12       Impact factor: 5.923

8.  Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value.

Authors:  Venkatramanujam Srinivasan; Charanjit Kaur; Seithikurippu Pandi-Perumal; Gregory M Brown; Daniel P Cardinali
Journal:  Int J Alzheimers Dis       Date:  2010-12-08

9.  Urinary 6-sulfatoxymelatonin level in age-related macular degeneration patients.

Authors:  Richard Rosen; Dan-Ning Hu; Violete Perez; Katy Tai; Guo-Pei Yu; Min Chen; Paul Tone; Steven A McCormick; Joseph Walsh
Journal:  Mol Vis       Date:  2009-08-21       Impact factor: 2.367

Review 10.  Melatonin: buffering the immune system.

Authors:  Antonio Carrillo-Vico; Patricia J Lardone; Nuria Alvarez-Sánchez; Ana Rodríguez-Rodríguez; Juan M Guerrero
Journal:  Int J Mol Sci       Date:  2013-04-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.